Currently, following the approval of TKIs including sorafenib [4], lenvatinib [5], regorafenib [6], and cabozantinib [7], for unresectable HCC, the combination therapy of programmed death ligand 1 (PD-L1) antibody, atezolizumab, and vascular endothelial growth factor (VEGF) antibody, bevacizumab, has been approved in a successful phase 3 clinical trial of IMbrave150 [8]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.